German court rules against GSK patent
This article was originally published in Scrip
Executive Summary
The Federal Patents Court in Munich has come out in favour of four generic firms, ruling that a combination patent for GlaxoSmithKline's top-selling inhaled respiratory product, Viani (salmeterol plus fluticasone propionate; also trademarked as Seretide/Advair), was not valid.